Despite the current downward trend of NVO, it is a good stock to retain in one's portfolio for long-term gains due to strong ...

Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.

Barclays analysts are bullish on Novo Nordisk (NYSE:NVO) stock ahead of the December release of pivotal clinical trial data ...

Upcoming data from a mid-stage study of Amgen's experimental weight-loss drug MariTide will shed light on how well it might ...

Novo Nordisk A/S shares slipped again on Tuesday, briefly erasing what was left of this year’s lofty gains, as concerns ...

Still, in the aftermath, Eli Lilly stock has dropped 4.8%. Novo Nordisk stock has shed 2.2%. Shares of Amgen, Pfizer and Roche have lost between 2% and 4%. Smaller biotech Structure Therapeutics has ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Novo Nordisk's (NVO) contract Ypsomed to supply the company with injection pens designed to deliver its next-gen obesity ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Over the last couple of years, Danish company Novo Nordisk (NYSE: NVO) has evolved from a relatively obscure pharmaceutical business to perhaps the biggest rising star in healthcare. The company's ...

I think that if you're an investor with a long-term time horizon, right now is a terrific opportunity to buy shares of Novo Nordisk. I see it as a compelling buy-and-hold stock, and believe that ...

Shares are trading at their lowest forward P/E multiples this year, thanks to a prolonged sell-off in the stock that's been going on since the late summer. As an investor in Novo Nordisk ...